Stem Holdings, Inc.

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224021397 Filed on May 24, 2024

Income Statement

Concept	2024 Q2	2023 Q3	2023

Balance Sheet

Concept	2023 Q3	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$961.0K	$961.0K
YoY Change	-36.94%	-36.94%
Cash & Equivalents	$961.0K	$961.0K
Short-Term Investments
Other Short-Term Assets	$11.06M	$11.06M
YoY Change	5401.49%	1090.31%
Inventory
Prepaid Expenses	$163.0K
Receivables
Other Receivables
Total Short-Term Assets	$13.32M	$13.32M
YoY Change	144.79%	144.79%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$28.00K	$28.00K
YoY Change	-99.89%	-99.89%
TOTAL ASSETS
Total Short-Term Assets	$13.32M	$13.32M
Total Long-Term Assets	$28.00K	$28.00K
Total Assets	$13.35M	$13.35M
YoY Change	-56.92%	-56.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.178M	$1.308M
YoY Change	-34.19%	-33.13%
Accrued Expenses	$91.00K	$91.00K
YoY Change	-88.82%	-88.82%
Deferred Revenue
YoY Change
Short-Term Debt	$229.0K	$2.340M
YoY Change	-49.22%	21.37%
Long-Term Debt Due	$400.0K
YoY Change	-60.0%
Total Short-Term Liabilities	$13.98M	$13.98M
YoY Change	123.9%	123.9%
LONG-TERM LIABILITIES
Long-Term Debt	$1.075M	$0.00
YoY Change	-51.69%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$1.075M	$0.00
YoY Change	-51.69%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.98M	$13.98M
Total Long-Term Liabilities	$1.075M	$0.00
Total Liabilities	$13.98M	$15.07M
YoY Change	0.24%	-2.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$152.0M
YoY Change	14.18%
Common Stock	$3.000K
YoY Change	-98.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.718M	-$1.718M
YoY Change
Total Liabilities & Shareholders Equity	$13.35M	$13.35M
YoY Change	-56.92%	-56.92%

Cashflow Statement

Concept	2024 Q2	2023 Q3	2023

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001697834
CY2022Q3	us-gaap	Restricted Cash RestrictedCash		usd
CY2022Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	STMH	Distribution Distribution		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2022	STMH	Noncash Interest And Rent NoncashInterestAndRent		usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty		usd
CY2023	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments		usd
CY2023	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	STMH	Noncash Repayment Of Finance Liability NoncashRepaymentOfFinanceLiability		usd
CY2022	STMH	Noncash Repayment Of Mortgages NoncashRepaymentOfMortgages		usd
CY2023	STMH	Financed Insurance FinancedInsurance		usd
CY2023	STMH	Interest Paid In Form Of Common Stock InterestPaidInFormOfCommonStock		usd
CY2022	STMH	Beneficial Conversion For Debt Discount BeneficialConversionForDebtDiscount		usd
CY2023	STMH	Refinancing Of Mortgage RefinancingOfMortgage		usd
CY2022	STMH	Conversion Of Debt And Accrued Interest To Equity ConversionOfDebtAndAccruedInterestToEquity		usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet		usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Goodwill1 DisposalGroupIncludingDiscontinuedOperationGoodwill1		usd
CY2023Q3	STMH	Discontinued Operations Convertible Notes Net DiscontinuedOperationsConvertibleNotesNet		usd
CY2023	STMH	Disposal Group Including Discontinued Operation Consulting Fees DisposalGroupIncludingDiscontinuedOperationConsultingFees		usd
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal Statement Of Income Extensible List DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTax
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal Statement Of Income Extensible List DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList	http://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTax
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive		usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive		usd
CY2023	STMH	Warrants Granted For Stockbased Compensation WarrantsGrantedForStockbasedCompensation		usd
CY2023	STMH	Warrants Granted For Stockbased Compensation Promissory Notes WarrantsGrantedForStockbasedCompensationPromissoryNotes		usd
CY2023	STMH	Options Issued Of Warrant Liability And Derivative Liability OptionsIssuedOfWarrantLiabilityAndDerivativeLiability		usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023	STMH	Cancellation Of Warrants Pursuant To Settlement Agreement CancellationOfWarrantsPursuantToSettlementAgreement		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	STMH	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loans Receivable DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLoansReceivable		usd
CY2022Q3	STMH	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loans Receivable DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLoansReceivable		usd
CY2023Q3	STMH	Deferred Tax Liabilities Deferred Revenue DeferredTaxLiabilitiesDeferredRevenue		usd
CY2022Q3	STMH	Deferred Tax Liabilities Deferred Revenue DeferredTaxLiabilitiesDeferredRevenue		usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	STMH	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted		usd
CY2022	STMH	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023	STMH	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted		usd
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023	STMH	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredIntrinsicValue		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55751
CY2023	dei	Entity Registrant Name EntityRegistrantName	STEM HOLDINGS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	61-1794883
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2201 NW Corporate Blvd.
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 205
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2023	dei	City Area Code CityAreaCode	(561)
CY2023	dei	Local Phone Number LocalPhoneNumber	948-5410
CY2023	dei	Security12b Title Security12bTitle	Common Stock par value $0.001
CY2023	dei	Trading Symbol TradingSymbol	STMH
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	Yes
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Public Float EntityPublicFloat	2965573	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6669910	shares
CY2023	dei	Auditor Name AuditorName	LJ Soldinger Associates, LLC
CY2023	dei	Auditor Location AuditorLocation	Deer Park, IL
CY2023	dei	Auditor Firm AuditorFirmId	318
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	961000	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1524000	usd
CY2023Q3	us-gaap	Restricted Cash RestrictedCash	545000	usd
CY2023Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1300000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	278000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416000	usd
CY2023Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	10235000	usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	29013000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	13319000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	30953000	usd
CY2023Q3	us-gaap	Assets Assets	13347000	usd
CY2022Q3	us-gaap	Assets Assets	30981000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1399000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1267000	usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2111000	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1073000	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	229000	usd
CY2022Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	438000	usd
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	448000	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	370000	usd
CY2023Q3	STMH	Warrant Liability WarrantLiability	134000	usd
CY2022Q3	STMH	Warrant Liability WarrantLiability	55000	usd
CY2023Q3	STMH	Liabilities Held For Sale LiabilitiesHeldForSale	9657000	usd
CY2022Q3	STMH	Liabilities Held For Sale LiabilitiesHeldForSale	10741000	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13978000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13944000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	13978000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	13944000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2810094	shares
CY2023Q3	STMH	Common Stock Shares Issuable CommonStockSharesIssuable	2810094	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2810094	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2270140	shares
CY2022Q3	STMH	Common Stock Shares Issuable CommonStockSharesIssuable	2270140	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2270140	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150471000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	148675000	usd
CY2023Q3	STMH	Distribution Distribution	-56000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152136000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133118000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1718000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	15559000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	1087000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	1478000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-631000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17037000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13347000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30981000	usd
CY2023	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	299000	usd
CY2022	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	682000	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	775000	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	2585000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2673000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3425000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	538000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	3747000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	7230000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-3747000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-7230000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1238000	usd
CY2022	us-gaap	Interest Expense InterestExpense	650000	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-78000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-31000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	79000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2327000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-46000	usd
CY2023	us-gaap	Other Income OtherIncome	18000	usd
CY2022	us-gaap	Other Income OtherIncome	1997000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	803000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-30000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1423000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4416000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5170000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2814000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-14239000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-14716000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-19409000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-17530000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-391000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-162000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-19018000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-17368000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-2.04
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-2.04
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.24
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.24
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.63
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-5.63
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-6.51
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-6.51
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.67
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.67
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.75
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.75
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2531668	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2261682	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2531668	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2261682	shares
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34234000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	285000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	30000	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	313000	usd
CY2022	STMH	Issuance Of Common Stock Related To Interest Expense IssuanceOfCommonStockRelatedToInterestExpense	121000	usd
CY2022	STMH	Stock Issued Related To Conversion Of Debt Value StockIssuedRelatedToConversionOfDebtValue	6000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	1046000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	158000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	454000	usd
CY2022	STMH	Issuance Of Warrants In Connection With Extension Of Debenture Maturity IssuanceOfWarrantsInConnectionWithExtensionOfDebentureMaturity	12000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-17530000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17037000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	17037000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	9000	usd
CY2023	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	23000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	250000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	87000	usd
CY2023	STMH	Distribution Related To Ventures DistributionRelatedToVentures	-56000	usd
CY2023	STMH	Issuance Of Common Stock Related To Interest Expense And Rent Expense IssuanceOfCommonStockRelatedToInterestExpenseAndRentExpense	220000	usd
CY2023	STMH	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Consulting Agreement AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteConsultingAgreement	153000	usd
CY2023	STMH	Issuance Of Warrants Stock In Connection With Convertible Debt IssuanceOfWarrantsStockInConnectionWithConvertibleDebt	9000	usd
CY2023	STMH	Issuance Of Common Stock In Connection With Employment Agreement IssuanceOfCommonStockInConnectionWithEmploymentAgreement	100000	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	816000	usd
CY2023	STMH	Issuance Of Shares In Connection With Advisory Agreement And Finders Fee IssuanceOfSharesInConnectionWithAdvisoryAgreementAndFindersFee	30000	usd
CY2023	STMH	Issuance Of Common Stock In Connection With Board Member Agreement IssuanceOfCommonStockInConnectionWithBoardMemberAgreement	100000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-19409000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-631000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-631000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-19409000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-17530000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-14239000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-14716000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-5170000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-2814000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	313000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	797000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	189000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	263000	usd
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	817000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	96000	usd
CY2023	STMH	Noncash Interest And Rent NoncashInterestAndRent	220000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	803000	usd
CY2023	STMH	Increase Decrease In Fair Value Of Warrants Liabilities IncreaseDecreaseInFairValueOfWarrantsLiabilities	-158000	usd
CY2022	STMH	Increase Decrease In Fair Value Of Warrants Liabilities IncreaseDecreaseInFairValueOfWarrantsLiabilities	2296000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	50000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-4000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	488000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property GainLossOnSaleOfProperty	1370000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-138000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-390000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-195000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-287000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3190000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5934000	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	1955000	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	987000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1235000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4947000	usd
CY2022	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	82000	usd
CY2022	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	1651000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1569000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	285000	usd
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1350000	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	133000	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	847000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1217000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-562000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-18000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3940000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1524000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5464000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1506000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1524000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	262000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	308000	usd
CY2022	STMH	Noncash Repayment Of Finance Liability NoncashRepaymentOfFinanceLiability	1092000	usd
CY2023	STMH	Noncash Repayment Of Mortgages NoncashRepaymentOfMortgages	1150000	usd
CY2022	STMH	Financed Insurance FinancedInsurance	449000	usd
CY2022	STMH	Interest Paid In Form Of Common Stock InterestPaidInFormOfCommonStock	67000	usd
CY2023	STMH	Beneficial Conversion For Debt Discount BeneficialConversionForDebtDiscount	816000	usd
CY2022	STMH	Refinancing Of Mortgage RefinancingOfMortgage	1100000	usd
CY2023	STMH	Conversion Of Debt And Accrued Interest To Equity ConversionOfDebtAndAccruedInterestToEquity	250000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80B_eus-gaap--NatureOfOperations_zsMqJ1jhRynb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <span id="xdx_820_zv7TdZiWR132">Incorporation and Operations and Going Concern</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stem Holdings, Inc. (“Stem” or the “Company”) is a Nevada corporation incorporated on June 7, 2016, and was operating as an a omnichannel, vertically-integrated cannabis branded products and technology company with state-of-the-art cultivation, processing, extraction, retail, distribution, and delivery-as-a-service (DaaS) operations throughout the United States. Stem’s family of award-winning brands includes TJ’s Gardens™, TravisxJames™, and Yerba Buena™ flower and extracts; Cannavore™ edible confections; and e-commerce delivery platforms provided direct-to consumer proprietary logistics and an omnichannel UX (user experience)/CX (customer experience). As of September 30, 2023, the Company has discontinued its cannabis operations , and all cannabis related assets are held-for-sale as of September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company had purchased, improved, leased, and operated , however, no longer invests in properties for use in the production, distribution and sales of cannabis and cannabis-infused products. Stem has ownership interests in 17 state issued cannabis licenses including nine (9) licenses for cannabis cultivation, two (2) licenses for cannabis processing, one (1) licenses for cannabis wholesale distribution, and five (5) cannabis dispensary licenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company has eight wholly-owned subsidiaries, including Stem Holdings Oregon, Inc., Stem Holdings IP, Inc., Opco, LLC, Stem Agri, Inc., Stem Holdings Oregon Acquisitions 1, Corp., Stem Holdings Oregon Acquisitions 2, Corp., Stem Holdings Oregon Acquisitions 3, Corp., Stem Holdings Oregon Acquisitions 4 Corp., 2336034 Alberta Ltd., Stem, through its subsidiaries, is currently in the process of seeking to be acquired by entities directly in the production and sale of cannabis. Driven Deliveries, Inc., a former wholly-owned subsidiary, was sold during the quarter ended December 31, 2021. 7LV USA Corporation, a former wholly-owned subsidiary, was sold during the quarter ended September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company’s stock is publicly traded and is listed on the Canadian Securities Exchange under the symbol “STEM” and the OTCQB exchange under the symbol “STMH”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In June 2021, the Company’s shareholders approved a proposal to amend the Company’s Articles of Incorporation to increase the number of authorized common shares from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210630__srt--RangeAxis__srt--MinimumMember_z1OgrPVCd7Y6" title="Common stock, shares authorized">300,000,000</span> shares to <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20210630__srt--RangeAxis__srt--MaximumMember_zq8SHWZA9Syc" title="Common stock, shares authorized">750,000,000</span> shares.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On December 27, 2023, the Company’s shareholders approved a proposal to implement a reverse split of the Company’s Common Stock within a range of one for ten shares and one for one-hundred shares, at the discretion of the Board of Directions prior to December 27, 2023. At this time, the Board of Directors has approved a reverse split utilizing a ratio of one share for each one-hundred shares to be implemented prior to December 27, 2023. As a result of the reverse split, <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20231227__20231227_zZ0jRLyf9ytg" title="Reverse stock split description">the Company’s <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_c20231227__20231227_zMrg1WrKyRdj" title="Reverse split">557,999,222</span> then outstanding shares were converted into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockSplits_c20231227__20231227_zQ0ytcZqXR74" title="Post split shares">5,579,992</span> post-split shares</span>. All fractional interests resulting f from the reverse split were rounded up to the nearest whole share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On September 30, 2023, the Company had approximate balances of cash, cash equivalents, and restricted cash of $<span id="xdx_90A_eus-gaap--RestrictedCashAndCashEquivalents_iI_pn5n6_c20230930_z0q5JxKN43j5" title="Cash, cash equivalents, and restricted cash">1.5</span> million, and working capital deficit of approximately $<span id="xdx_904_ecustom--WorkingCapital_iI_pn5n6_di_c20230930_zgwy4fahzna2" title="Working capital">0.7</span>million, and an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20230930_zF1WJWsYeU7d" title="Accumulated deficit">152</span> million.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">These audited consolidated financial statements have been prepared on a going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The United States federal government regulates drugs in large part through the Controlled Substances Act or CSA. Marijuana, which refers to certain parts and derivatives of the cannabis plant, is classified as a Schedule I controlled substance. As a Schedule I controlled substance, the federal Drug Enforcement Agency, or DEA, considers marijuana to have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use of the drug under medical supervision. According to the U.S. federal government, cannabis having a concentration of tetrahydrocannabinol, or THC, greater than 0.3% is marijuana. Cannabis with a THC content below 0.3% is classified as hemp. The scheduling of marijuana as a Schedule I controlled substance is inconsistent with what we believe to be widely accepted medical uses for marijuana by physicians, researchers, customers, and others. Moreover, as of December 31, 2021, and despite the conflict with U.S. federal law, at least 36 states, the District of Columbia, the Commonwealth of the Northern Mariana Islands, Guam, Puerto Rico, and the U.S. Virgin Islands have legalized marijuana for medical use. Eighteen of those states and the District of Columbia, the Commonwealth of the Northern Mariana Islands, and Guam have legalized the adult use of cannabis for recreational purposes. In November 2020, voters in Arizona, Montana, New Jersey, and South Dakota voted by referendum to legalize marijuana for adult use, and voters in Mississippi and South Dakota voted to legalize marijuana for medical use, although South Dakota’s adult-use measure has been declared unconstitutional by the State Supreme Court. In 2021, the states of Connecticut, New Mexico, New York, and Virginia enacted laws legalizing the adult use of cannabis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Marijuana is largely regulated at the state level in the United States. State laws regulating marijuana conflict with the CSA, making marijuana use and possession federally illegal. Although certain states and territories of the United States authorize medical or adult-use marijuana production and distribution by licensed or registered entities, under United States federal law, the possession, use, cultivation, and transfer of marijuana and any related drug paraphernalia is illegal. Although our activities are compliant with the applicable state and local laws in those states where we maintain such licenses, strict compliance with state and local laws with respect to cannabis may neither absolve us of liability under United States federal law nor provide a defense to any federal criminal action that may be brought against us.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In 2013, as more and more states began to legalize medical and/or adult-use marijuana, the federal government attempted to provide clarity on the incongruity between federal law and these state-legal regulatory frameworks. Until 2018, the federal government provided guidance to federal agencies and banking institutions through a series of DOJ memoranda. The most notable of this guidance came in the form of a memorandum issued by former U.S. Deputy Attorney General James Cole on August 29, 2013, which we refer to as the Cole Memorandum.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Cole Memorandum offered guidance to federal agencies on how to prioritize civil enforcement, criminal investigations, and prosecutions regarding marijuana in all states and quickly set a standard with which marijuana-related businesses would comply. The Cole Memorandum put forth eight prosecution priorities:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">1. Preventing the distribution of marijuana to minors;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">2. Preventing revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">3. Preventing the diversion of marijuana from states where it is legal under state law in some form to other states;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">4. Preventing the state-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">5. Preventing violence and the use of firearms in the cultivation and distribution of marijuana;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">6. Preventing drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">7. Preventing the growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">8. Preventing marijuana possession or use on federal property.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On January 4, 2018, former United States Attorney General Sessions rescinded the Cole Memorandum by issuing a new memorandum to all United States Attorneys, which we refer to as the Sessions Memo. Rather than establishing national enforcement priorities particular to marijuana-related crimes in jurisdictions where certain marijuana activity was legal under state law, the Sessions Memo simply rescinded the Cole Memorandum and other Department of Justice memorandums providing prosecutorial guidance on state and tribally authorized medical and adult-use cannabis activities and instructed that “[i]n deciding which marijuana activities to prosecute... with the [DOJ’s] finite resources, prosecutors should follow the well- established principles that govern all federal prosecutions.” Namely, these include the seriousness of the offense, history of criminal activity, deterrent effect of prosecution, the interests of victims, and other principles.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">On January 21, 2021, Joseph R. Biden, Jr. was sworn in as President of the United States. President Biden’s Attorney General, Merrick Garland, was confirmed by the United States Senate on March 10, 2021. It is not yet known whether the Department of Justice, under President Biden and Attorney General Garland, will re-adopt the Cole Memorandum or announce a substantive marijuana enforcement policy. During his Senate confirmation, Merrick Garland told Senator Cory Booker (D-NJ), “It does not seem to me useful the use of limited resources that we have to be pursuing prosecutions in states that have legalized and are regulating the use of marijuana, either medically or otherwise.” Such statements are not official declarations or policies of the DOJ and are not binding on the DOJ, any United States Attorney, or the United States federal courts. Substantial uncertainty regarding United States federal enforcement remains. To date, there have been no new federal cannabis memorandums issued by the Biden Administration or any published change in federal enforcement policy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Nonetheless, there is no guarantee that state laws legalizing and regulating the sale and use of marijuana will not be repealed or overturned or that local government authorities will not limit the applicability of state laws within their respective jurisdictions. Unless and until the United States Congress amends the CSA with respect to marijuana (and as to the timing or scope of any such potential amendments, there can be no assurance), there is a risk that federal authorities may enforce current U.S. federal law. Currently, in the absence of uniform federal guidance, as had been established by the Cole Memorandum, enforcement priorities are determined by respective United States Attorneys.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As an industry best practice, despite the rescission of the Cole Memorandum, we abide by the following standard operating policies and procedures, which are designed to ensure compliance with the guidance provided by the Cole Memorandum:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 34.55pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">1. Continuously monitor our operations for compliance with all licensing requirements as established by the applicable state, county, municipality, town, township, borough, and other political/administrative divisions;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">2. Ensure that our cannabis-related activities adhere to the scope of the licensing obtained (for example: in the states where cannabis is permitted only for adult-use, the products are only sold to individuals who meet the requisite age requirements);</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">3. Implement policies and procedures to prevent the distribution of our cannabis products to minors;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">4. Implement policies and procedures in place to avoid the distribution of the proceeds from our operations to criminal enterprises, gangs, or cartels;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">5. Implement an inventory tracking system and necessary procedures to reliably track inventory and prevent the diversion of cannabis or cannabis products into those states where cannabis is not permitted by state law or across any state lines in general;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">6. Monitor the operations at our facilities so that our state-authorized cannabis business activity is not used as a cover or pretense for trafficking of other illegal drugs or engaging in any other illegal activity; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 23.45pt; text-align: justify">7. Implement quality controls so that our products comply with applicable regulations and contain necessary disclaimers about the contents of the products to avoid adverse public health consequences from cannabis use and discourage impaired driving.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In addition, we frequently conduct background checks to confirm that the principals and management of our operating subsidiaries are of good character and have not been involved with other illegal drugs, engaged in illegal activity or activities involving violence, or the use of firearms in the cultivation, manufacturing, or distribution of cannabis. We also conduct ongoing reviews of the activities of our cannabis businesses, the premises on which they operate, and the policies and procedures related to the possession of cannabis or cannabis products outside of the licensed premises. Moreover, in recent years, certain temporary federal legislative enactments that protect the medical marijuana and hemp industries have also been in effect. For instance, certain marijuana businesses receive a measure of protection from federal prosecution by operation of temporary appropriations measures that have been enacted into law as amendments (or “riders”) to federal spending bills passed by Congress and signed by Presidents Obama, Trump, and, most recently, President Biden. For instance, in the Appropriations Act of 2015, Congress included a budget “rider” that prohibits DOJ from expending any funds to enforce any law that interferes with a state’s implementation of its own medical marijuana laws. The rider originally known as the “Rohrbacher-Farr” Amendment after its original lead sponsors is now known as the “Joyce” Amendment after its current sponsor. Originally, a Republican-controlled House and Democratic-controlled Senate passed the Rohrbacher-Farr Amendment. The bill was “a bipartisan appropriations measure that looks to prohibit the DEA from spending funds to arrest state-licensed medical marijuana patients and providers.” Subsequently, the rider t has been included in multiple budgets passed by successive Congresses controlled by both major political parties. Most recently, on February 18, 2022, the Amendment was renewed through the signing of an additional stopgap spending bill, H.R.6617 - Further Additional Extending Government Funding Act, effective through March 11, 2022. While the Amendment has been included in successive appropriations legislation or resolutions since 2015, its inclusion or non-inclusion is subject to political change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Notably, Joyce Amendment has applied only to medical marijuana programs and has not provided the same protections to enforcement against adult-use activities. If the Amendment is no longer in effect, the risk of federal enforcement and override of state marijuana laws would increase.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In December 2019, an outbreak of a novel strain of coronavirus (COVID-19) originated in Wuhan, China, and has since spread to several other countries, including the United States. On June 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. In addition, as of the time of the filing of this Annual Report on Form 10-K, several states in the United States have declared states of emergency, and several countries around the world, including the United States, have taken steps to restrict travel. The existence of a worldwide pandemic, the fear associated with COVID-19, or any, pandemic, and the reactions of governments in response to COVID-19, or any, pandemic, to regulate the flow of labor and products and impede the travel of personnel, may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Disruptions to our supply chain and business operations disruptions to our retail operations and our ability to collect rent from the properties which we own, personnel absences, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects throughout our business. If we need to close any of our facilities or a critical number of our employees become too ill to work, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the markets in which we operate. Any of these uncertainties could have a material adverse effect on our business, financial condition, or results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Should the United States Federal Government choose to begin enforcement of the provisions under the “ACT”, the Company through its wholly owned subsidiaries could be prosecuted under the “ACT” and the Company may have to immediately cease operations and/or be liquidated upon its closing of the acquisition or investment in entities that engage directly in the production and or sale of cannabis.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Management believes that the Company has access to capital resources through potential public or private issuances of debt or equity securities. However, if the Company is unable to raise additional capital, it may be required to curtail operations and take additional measures to reduce costs, including reducing its workforce, eliminating outside consultants, and reducing legal fees to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company’s 557,999,222 then outstanding shares were converted into 5,579,992 post-split shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Reverse Stock Splits StockIssuedDuringPeriodSharesReverseStockSplits	557999222	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	5579992	shares
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1500000	usd
CY2023Q3	STMH	Working Capital WorkingCapital	-700000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-152000000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zqewAj0YsgWj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86D_zuS3J1JKfbHa">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income, and expenses. The most significant estimates included in these consolidated financial statements are those associated with the assumptions used to value equity instruments, valuation of its long-lived assets for impairment testing, valuation of intangible assets, the valuation of inventory and assets and liabilities held for sale. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable given the circumstances that exist at the time the financial statements are prepared. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </i></b></p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAFbwB6LtFyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_zUnGV0Dgd8Qi">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Certain amounts in the Company’s consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2023Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	0	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	4	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	79	usd
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	usd
CY2023	STMH	Investments Impairment InvestmentsImpairment	0	usd
CY2022	STMH	Investments Impairment InvestmentsImpairment	795000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1500000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	5900000	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	2600000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	1900000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1224000	usd
CY2023	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p id="xdx_84B_eus-gaap--DerivativesEmbeddedDerivatives_zCdMV4jNct01" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_zfXrMCxkPDEg">Embedded Conversion Features</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company evaluates embedded conversion features within convertible debt to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in the statement of operations. If the conversion feature does not require recognition of a bifurcated derivative, the convertible debt instrument is evaluated for consideration of any beneficial conversion feature (“BCF”) requiring separate recognition. When the Company records a BCF, the intrinsic value of the BCF is recorded as a debt discount against the face amount of the respective debt instrument (offset to additional paid-in capital) and amortized to interest expense over the life of the debt.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P177M
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1370000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1224000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1370000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_845_eus-gaap--ConcentrationRiskCreditRisk_zZf8OiswpOn1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><b style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_864_z3uUgrTglYs3">Geographical Concentrations</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of September 30, 2022, the Company is primarily engaged in the production and sale of cannabis, which is only legal for recreational use in 19 states and D.C., with lesser legalization, such as for medical use in an additional 21 states and D.C., as of the time of these consolidated financial statements. In addition, the United States Congress has passed legislation, specifically the Agriculture Improvement Act of 2018 (also known as the “Farm Bill”) that has removed production and consumption of hemp and associated products from Schedule 1 of the Controlled Substances Act.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	884645	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10381	shares
CY2023	us-gaap	Advertising Expense AdvertisingExpense	103000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	266000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Accounts Receivable Net Of Allowance For Doubtful Accounts DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNetOfAllowanceForDoubtfulAccounts	158000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Accounts Receivable Net Of Allowance For Doubtful Accounts DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNetOfAllowanceForDoubtfulAccounts	313000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	166000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Inventory1 DisposalGroupIncludingDiscontinuedOperationInventory1	894000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Inventory1 DisposalGroupIncludingDiscontinuedOperationInventory1	2675000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets	360000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Prepaid And Other Assets DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssets	513000	usd
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	1578000	usd
CY2022Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	3501000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	2321000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	9089000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Deposits And Other Assets DisposalGroupIncludingDiscontinuedOperationDepositsAndOtherAssets	13000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Deposits And Other Assets DisposalGroupIncludingDiscontinuedOperationDepositsAndOtherAssets	13000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Right Of Use Asset DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset	6039000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Right Of Use Asset DisposalGroupIncludingDiscontinuedOperationRightOfUseAsset	6874000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets DisposalGroupIncludingDiscontinuedOperationIntangibleAssets	284000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets DisposalGroupIncludingDiscontinuedOperationIntangibleAssets	8014000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Goodwill1 DisposalGroupIncludingDiscontinuedOperationGoodwill1	1522000	usd
CY2023Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	10235000	usd
CY2022Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation AssetsOfDisposalGroupIncludingDiscontinuedOperation	29013000	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities	623000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilities	1043000	usd
CY2022Q3	STMH	Discontinued Operations Convertible Notes Net DiscontinuedOperationsConvertibleNotesNet	404000	usd
CY2023Q3	STMH	Discontinued Operations Current Maturities Of Longterm Debt DiscontinuedOperationsCurrentMaturitiesOfLongtermDebt	400000	usd
CY2022Q3	STMH	Discontinued Operations Current Maturities Of Longterm Debt DiscontinuedOperationsCurrentMaturitiesOfLongtermDebt	1000000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Short Term Notes And Advances DisposalGroupIncludingDiscontinuedOperationShortTermNotesAndAdvances	6000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Short Term Notes And Advances DisposalGroupIncludingDiscontinuedOperationShortTermNotesAndAdvances	13000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Lease Liability Current DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityCurrent	430000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Lease Liability Current DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityCurrent	580000	usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1459000	usd
CY2022Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	3040000	usd
CY2023Q3	STMH	Disposal Group Including Discontinued Operation Lease Liability Non Current DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityNonCurrent	7523000	usd
CY2022Q3	STMH	Disposal Group Including Discontinued Operation Lease Liability Non Current DisposalGroupIncludingDiscontinuedOperationLeaseLiabilityNonCurrent	6476000	usd
CY2023Q3	STMH	Discontinued Operations Longterm Debt Mortgages DiscontinuedOperationsLongtermDebtMortgages	675000	usd
CY2022Q3	STMH	Discontinued Operations Longterm Debt Mortgages DiscontinuedOperationsLongtermDebtMortgages	1225000	usd
CY2023Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	9657000	usd
CY2022Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation	10741000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	14158000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	16563000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	12126000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	14440000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	2032000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	2123000	usd
CY2022	STMH	Disposal Group Including Discontinued Operation Consulting Fees DisposalGroupIncludingDiscontinuedOperationConsultingFees	2000	usd
CY2023	STMH	Disposal Group Including Discontinued Operation Professional Fees DisposalGroupIncludingDiscontinuedOperationProfessionalFees	68000	usd
CY2022	STMH	Disposal Group Including Discontinued Operation Professional Fees DisposalGroupIncludingDiscontinuedOperationProfessionalFees	87000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	5521000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	7700000	usd
CY2023	STMH	Disposal Group Including Discontinued Operation Impairment Expense DisposalGroupIncludingDiscontinuedOperationImpairmentExpense	6832000	usd
CY2022	STMH	Disposal Group Including Discontinued Operation Impairment Expense DisposalGroupIncludingDiscontinuedOperationImpairmentExpense	8132000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	12421000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	15921000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-10389000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-13798000	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	61000	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Foreign Currency Translation Gains Losses DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses	-4000	usd
CY2023	STMH	Disposal Group Including Discontinued Operation Loss From Disposal Of Subsidiary DisposalGroupIncludingDiscontinuedOperationLossFromDisposalOfSubsidiary	-3911000	usd
CY2022	STMH	Disposal Group Including Discontinued Operation Loss From Disposal Of Subsidiary DisposalGroupIncludingDiscontinuedOperationLossFromDisposalOfSubsidiary	-914000	usd
CY2023	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-3850000	usd
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-918000	usd
CY2023	STMH	Income Loss From Discontinued Operations Net Tax IncomeLossFromDiscontinuedOperationsNetTax	-14239000	usd
CY2022	STMH	Income Loss From Discontinued Operations Net Tax IncomeLossFromDiscontinuedOperationsNetTax	-14716000	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	163000	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	100000	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	115000	usd
CY2022Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	316000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	278000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	416000	usd
CY2022	STMH	Non Controlling Interest Equity Shares NonControllingInterestEquityShares	1640000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-162000	usd
CY2022Q3	us-gaap	Minority Interest MinorityInterest	1478000	usd
CY2023	STMH	Non Controlling Interest Equity Shares NonControllingInterestEquityShares	1478000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-391000	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	1087000	usd
CY2023Q1	us-gaap	Limited Liability Company Or Limited Partnership Business Activities And Description LimitedLiabilityCompanyOrLimitedPartnershipBusinessActivitiesAndDescription	The first 35 installments will be $5,278 and the last payment will be $5,278. The Company realized a loss on sale of approximately $18,000.
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1178000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1140000	usd
CY2023Q3	STMH	Accrued Liabilities Credit Cards AccruedLiabilitiesCreditCards	14000	usd
CY2022Q3	STMH	Accrued Liabilities Credit Cards AccruedLiabilitiesCreditCards	14000	usd
CY2023Q3	us-gaap	Interest Payable Current InterestPayableCurrent	77000	usd
CY2022Q3	us-gaap	Interest Payable Current InterestPayableCurrent	113000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	130000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1399000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1267000	usd
CY2023Q3	STMH	Equipment Financing EquipmentFinancing	15000	usd
CY2022Q3	STMH	Equipment Financing EquipmentFinancing	20000	usd
CY2023Q3	STMH	Insurance Financing InsuranceFinancing	64000	usd
CY2022Q3	STMH	Insurance Financing InsuranceFinancing	126000	usd
CY2023Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	150000	usd
CY2022Q3	us-gaap	Secured Debt Current SecuredDebtCurrent	292000	usd
CY2023Q3	STMH	Notes Payable And Advances NotesPayableAndAdvances	229000	usd
CY2022Q3	STMH	Notes Payable And Advances NotesPayableAndAdvances	438000	usd
CY2020Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	354000	usd
CY2020Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	249000	usd
CY2023	us-gaap	Payments For Rent PaymentsForRent	11667	usd
CY2023	STMH	Base Rental Fee Percentage BaseRentalFeePercentage	0.02	pure
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	400000	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	675000	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1075000	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	400000	usd
CY2023Q3	STMH	Secured Long Term Debts SecuredLongTermDebts	675000	usd
CY2023Q3	STMH	Warrant Liability WarrantLiability	134000	usd
CY2023Q3	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	448000	usd
CY2023Q3	STMH	Fair Value Of Warrant Liability And Embedded Derivative Liability FairValueOfWarrantLiabilityAndEmbeddedDerivativeLiability	582000	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2277000	usd
CY2022	STMH	Warrants Granted For Stockbased Compensation WarrantsGrantedForStockbasedCompensation	105000	usd
CY2022	STMH	Modification Of Debentures ModificationOfDebentures	339000	usd
CY2022	STMH	Change In Fair Value Of Warrant Liability And Derivative Liability ChangeInFairValueOfWarrantLiabilityAndDerivativeLiability	-2296000	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	425000	usd
CY2023	STMH	Change In Fair Value Of Warrant Liability And Derivative Liability ChangeInFairValueOfWarrantLiabilityAndDerivativeLiability	157000	usd
CY2023Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	582000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4852000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4382000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3193000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3272000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-58000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-58000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1717000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1168000	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	the expected tax benefit, temporary timing differences and long-term timing differences are calculated at the 25% statutory rate.
CY2022	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	the expected tax benefit, temporary timing differences and long-term timing differences are calculated at the 25% statutory rate.
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25	pure
CY2023Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11769	usd
CY2022Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10110	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3171	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3045	usd
CY2023Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	1708	usd
CY2022Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Impairment Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses	2011	usd
CY2023Q3	STMH	Deferred Tax Asset Gross DeferredTaxAssetGross	16648	usd
CY2022Q3	STMH	Deferred Tax Asset Gross DeferredTaxAssetGross	15166	usd
CY2023Q3	STMH	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	49	usd
CY2022Q3	STMH	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	39	usd
CY2023Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	49	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	39	usd
CY2023Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16599	usd
CY2022Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15127	usd
CY2023Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16599	usd
CY2022Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15127	usd
CY2023Q3	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	37000000	usd
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	32236	shares
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	285000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	17.00
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	7.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y7M28D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P2Y6M7D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.63	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.24	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0472	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0242	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	66979	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	107.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y1M2D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	15000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.00
CY2022	STMH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P3Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	22422	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	67.00
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	59557	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	107.00
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y10M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	74250	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.00
CY2023	STMH	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermGranted	P3Y2M26D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	6000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	127807	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.67
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M28D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	125932	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.00
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M6D
CY2021Q2	STMH	Base Rental Fee Percentage BaseRentalFeePercentage	0.025	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	503000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1013000	usd
CY2016Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P10Y
CY2016Q3	us-gaap	Payments For Rent PaymentsForRent	7033	usd
CY2016Q3	us-gaap	Sale Leaseback Transaction Other Payments Required SaleLeasebackTransactionOtherPaymentsRequired	315	usd
CY2016Q3	STMH	Percentage Of Base Rental Fees Escalation PercentageOfBaseRentalFeesEscalation	0.02	pure
CY2016Q3	us-gaap	Security Deposit SecurityDeposit	14000	usd
CY2018Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	On February 22, 2018, both parties executed a lease addendum that adds contiguous property for 12,322 square feet. The term commences November 1, 2017, and continues through November 31, 2026, at a starting rate of $3,525 a month that escalates after the first year. The Company subleases this property to a related party (see disclosures below under “Springfield Suites”). As of September 30, 2023, Company eliminates this rental income in consolidation.
CY2018Q1	us-gaap	Area Of Land AreaOfLand	12322	sqft
CY2018Q1	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	3525	usd
CY2019Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P4Y
CY2019Q3	us-gaap	Payments For Rent PaymentsForRent	4285	usd
CY2020Q4	us-gaap	Area Of Land AreaOfLand	2000	sqft
CY2019Q1	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P5Y
CY2019Q1	us-gaap	Payments For Rent PaymentsForRent	9696	usd
CY2021Q2	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P15Y
CY2021Q2	us-gaap	Payments For Rent PaymentsForRent	31500	usd

Files In Submission

Name	View Source	Status
0001493152-24-021397-index-headers.html	Edgar Link	pending
0001493152-24-021397-index.html	Edgar Link	pending
0001493152-24-021397.txt	Edgar Link	pending
0001493152-24-021397-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stmh-20230930.xsd	Edgar Link	pending
stmh-20230930_def.xml	Edgar Link	unprocessable
stmh-20230930_lab.xml	Edgar Link	unprocessable
stmh-20230930_pre.xml	Edgar Link	unprocessable
stmh-20230930_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Stem Holdings, Inc.

2024 Q2 Form 10-K Financial Statement

#000149315224021397 Filed on May 24, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission